Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus

S. T. Crooke, R. L. Comis, Lawrence Einhorn, J. E. Strong, A. Broughton, A. W. Prestayko

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The clinical pharmacology of bleomycin administered as an i.v. bolus has been studied in a homogeneous group of patients receiving a single regimen containing bleomycin, vinblastine, and cis dichlorodiammineplatinum(II). These studies demonstrated that in patients with creatinine clearance ≥ 35 ml/min, the serum (or plasma) terminal elimination half life of bleomycin was approximately 115 min. In patients with creatinine clearances <25-35 ml/min, the terminal elimination half life increased exponentially as the creatinine clearance decreased. The volume of distribution was approximately 20 l, and was unaffected by changes in the creatinine clearance. The microbiologic assay and radioimmunoassay employed gave equivalent results.

Original languageEnglish (US)
Pages (from-to)1631-1636
Number of pages6
JournalCancer Treatment Reports
Volume61
Issue number9
StatePublished - 1977
Externally publishedYes

Fingerprint

Clinical Pharmacology
Bleomycin
Creatinine
Kidney
Half-Life
Vinblastine
Cisplatin
Radioimmunoassay
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Crooke, S. T., Comis, R. L., Einhorn, L., Strong, J. E., Broughton, A., & Prestayko, A. W. (1977). Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. Cancer Treatment Reports, 61(9), 1631-1636.

Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. / Crooke, S. T.; Comis, R. L.; Einhorn, Lawrence; Strong, J. E.; Broughton, A.; Prestayko, A. W.

In: Cancer Treatment Reports, Vol. 61, No. 9, 1977, p. 1631-1636.

Research output: Contribution to journalArticle

Crooke, ST, Comis, RL, Einhorn, L, Strong, JE, Broughton, A & Prestayko, AW 1977, 'Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus', Cancer Treatment Reports, vol. 61, no. 9, pp. 1631-1636.
Crooke, S. T. ; Comis, R. L. ; Einhorn, Lawrence ; Strong, J. E. ; Broughton, A. ; Prestayko, A. W. / Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. In: Cancer Treatment Reports. 1977 ; Vol. 61, No. 9. pp. 1631-1636.
@article{64b62484e30c4302beb0b22302c08eaf,
title = "Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus",
abstract = "The clinical pharmacology of bleomycin administered as an i.v. bolus has been studied in a homogeneous group of patients receiving a single regimen containing bleomycin, vinblastine, and cis dichlorodiammineplatinum(II). These studies demonstrated that in patients with creatinine clearance ≥ 35 ml/min, the serum (or plasma) terminal elimination half life of bleomycin was approximately 115 min. In patients with creatinine clearances <25-35 ml/min, the terminal elimination half life increased exponentially as the creatinine clearance decreased. The volume of distribution was approximately 20 l, and was unaffected by changes in the creatinine clearance. The microbiologic assay and radioimmunoassay employed gave equivalent results.",
author = "Crooke, {S. T.} and Comis, {R. L.} and Lawrence Einhorn and Strong, {J. E.} and A. Broughton and Prestayko, {A. W.}",
year = "1977",
language = "English (US)",
volume = "61",
pages = "1631--1636",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus

AU - Crooke, S. T.

AU - Comis, R. L.

AU - Einhorn, Lawrence

AU - Strong, J. E.

AU - Broughton, A.

AU - Prestayko, A. W.

PY - 1977

Y1 - 1977

N2 - The clinical pharmacology of bleomycin administered as an i.v. bolus has been studied in a homogeneous group of patients receiving a single regimen containing bleomycin, vinblastine, and cis dichlorodiammineplatinum(II). These studies demonstrated that in patients with creatinine clearance ≥ 35 ml/min, the serum (or plasma) terminal elimination half life of bleomycin was approximately 115 min. In patients with creatinine clearances <25-35 ml/min, the terminal elimination half life increased exponentially as the creatinine clearance decreased. The volume of distribution was approximately 20 l, and was unaffected by changes in the creatinine clearance. The microbiologic assay and radioimmunoassay employed gave equivalent results.

AB - The clinical pharmacology of bleomycin administered as an i.v. bolus has been studied in a homogeneous group of patients receiving a single regimen containing bleomycin, vinblastine, and cis dichlorodiammineplatinum(II). These studies demonstrated that in patients with creatinine clearance ≥ 35 ml/min, the serum (or plasma) terminal elimination half life of bleomycin was approximately 115 min. In patients with creatinine clearances <25-35 ml/min, the terminal elimination half life increased exponentially as the creatinine clearance decreased. The volume of distribution was approximately 20 l, and was unaffected by changes in the creatinine clearance. The microbiologic assay and radioimmunoassay employed gave equivalent results.

UR - http://www.scopus.com/inward/record.url?scp=0017593101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017593101&partnerID=8YFLogxK

M3 - Article

C2 - 74282

AN - SCOPUS:0017593101

VL - 61

SP - 1631

EP - 1636

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9

ER -